Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. More Details
No risks detected for ABMD from our risk checks.
Flawless balance sheet with limited growth.
Share Price & News
How has Abiomed's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ABMD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: ABMD's weekly volatility (5%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: ABMD exceeded the US Medical Equipment industry which returned 28% over the past year.
Return vs Market: ABMD exceeded the US Market which returned 29.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Abiomed's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StHas Abiomed (NASDAQ:ABMD) Got What It Takes To Become A Multi-Bagger?
1 month ago | Simply Wall StResults: Abiomed, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
1 month ago | Simply Wall StAre Abiomed's (NASDAQ:ABMD) Statutory Earnings A Good Guide To Its Underlying Profitability?
Is Abiomed undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ABMD ($307.6) is trading above our estimate of fair value ($25.49)
Significantly Below Fair Value: ABMD is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ABMD is poor value based on its PE Ratio (69.2x) compared to the US Medical Equipment industry average (51.7x).
PE vs Market: ABMD is poor value based on its PE Ratio (69.2x) compared to the US market (21.4x).
Price to Earnings Growth Ratio
PEG Ratio: ABMD is poor value based on its PEG Ratio (5.6x)
Price to Book Ratio
PB vs Industry: ABMD is overvalued based on its PB Ratio (11x) compared to the US Medical Equipment industry average (5.2x).
How is Abiomed forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABMD's forecast earnings growth (12.4% per year) is above the savings rate (2%).
Earnings vs Market: ABMD's earnings (12.4% per year) are forecast to grow slower than the US market (19.6% per year).
High Growth Earnings: ABMD's earnings are forecast to grow, but not significantly.
Revenue vs Market: ABMD's revenue (15% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: ABMD's revenue (15% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ABMD's Return on Equity is forecast to be low in 3 years time (15.2%).
How has Abiomed performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABMD has high quality earnings.
Growing Profit Margin: ABMD's current net profit margins (24.7%) are lower than last year (29.1%).
Past Earnings Growth Analysis
Earnings Trend: ABMD's earnings have grown significantly by 28.3% per year over the past 5 years.
Accelerating Growth: ABMD's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ABMD had negative earnings growth (-18.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (9.8%).
Return on Equity
High ROE: ABMD's Return on Equity (15.9%) is considered low.
How is Abiomed's financial position?
Financial Position Analysis
Short Term Liabilities: ABMD's short term assets ($693.7M) exceed its short term liabilities ($120.4M).
Long Term Liabilities: ABMD's short term assets ($693.7M) exceed its long term liabilities ($46.6M).
Debt to Equity History and Analysis
Debt Level: ABMD is debt free.
Reducing Debt: ABMD has not had any debt for past 5 years.
Debt Coverage: ABMD has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ABMD has no debt, therefore coverage of interest payments is not a concern.
What is Abiomed current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ABMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ABMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ABMD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ABMD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ABMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Minogue (53 yo)
Mr. Michael R. Minogue, also known as Mike, has been Chief Executive Officer and President of ABIOMED Europe GmbH since April 2004. Mr. Minogue has been Chief Executive Officer, President and Director of A...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD16.61M) is above average for companies of similar size in the US market ($USD10.53M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
|CFO & VP||2.92yrs||US$3.07m||0.0068% |
|Senior VP & COO||13.92yrs||US$2.66m||0.32% |
|VP & GM of Global Sales||12yrs||US$1.71m||0.15% |
|VP & Chief Commercial Officer||1.92yrs||US$2.82m||0.088% |
|VP & CTO||no data||no data||no data|
|Director of Investor Relations||6.5yrs||no data||no data|
|VP, General Counsel & Secretary||3.17yrs||no data||0.0099% |
|Communications Manager||no data||no data||no data|
|Head of Global Human Resources||1.5yrs||no data||no data|
|VP & Chief Medical Officer||0.75yr||no data||no data|
|VP & Corporate Controller||13.33yrs||US$1.49m||no data|
Experienced Management: ABMD's management team is considered experienced (4.8 years average tenure).
|Independent Director||12.83yrs||US$267.50k||0.39% |
|Independent Director||5.08yrs||US$267.50k||0.018% |
|Independent Director||9.83yrs||US$270.00k||0.014% |
|Director Emeritus||4.58yrs||US$255.00k||no data|
|Independent Director||6.58yrs||US$260.00k||0.031% |
|Independent Lead Director||15.42yrs||US$295.00k||0.030% |
|Independent Director||5.08yrs||US$265.00k||0.013% |
|Director||0.083yr||no data||no data|
Experienced Board: ABMD's board of directors are considered experienced (6.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Abiomed, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Abiomed, Inc.
- Ticker: ABMD
- Exchange: NasdaqGS
- Founded: 1981
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$13.913b
- Shares outstanding: 45.23m
- Website: https://www.abiomed.com
Number of Employees
- Abiomed, Inc.
- 22 Cherry Hill Drive
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ABMD||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jul 1987|
|AIO||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 1987|
|0H7S||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jul 1987|
|ABMD *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jul 1987|
|A1BM34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 4 REPR 1 COM||BR||BRL||Jan 2020|
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patient...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/03/04 23:27|
|End of Day Share Price||2021/03/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.